Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Diabetes is the most common cause of chronic kidney disease (CKD). Around 33 percent of adults with diabetes also have CKD. When diabetes causes CKD, its sometimes called diabetic kidney disease.

A major study suggests that the cardiovascular benefits of certain diabetes medications can fade within months after stopping ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

The diabetes drug you've heard of for 60 years just revealed a secret — it's been working on your brain all along.

Oral semaglutide improved multiple cardiometabolic metrics among adults with type 2 diabetes at high risk for atherosclerotic ...

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular ...